OcuRing-K™: The Dropless Cataract Surgery Solution

3/16/2021 16:50 - 17:35

  • Eye drops have significant limitations with respect to compliance, safety/tolerability, ocular bioavailability, and economic costs to the healthcare system 
  • There is growing interest in “dropless” technologies that eliminate the burden of topical eye drops after cataract surgery 
  • OcuRing-K™ (ketorolac implant) is the is the only steroid-sparing dropless therapy that eliminates the need for topical anti-inflammatory eye drops in cataract surgery   

Kenneth J. Mandell, Founder and CEO, LayerBio